Starling Oncology, Inc. (STLN)
| Market Cap | 356.97M +13.6% |
| Revenue (ttm) | 620.45M +34.6% |
| Net Income | -30.03M |
| EPS | -0.29 |
| Shares Out | 101.99M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 21,710,152 |
| Open | 3.760 |
| Previous Close | 3.750 |
| Day's Range | 3.300 - 3.775 |
| 52-Week Range | 2.320 - 7.130 |
| Beta | 0.41 |
| Analysts | Strong Buy |
| Price Target | 9.25 (+164.29%) |
| Earnings Date | Nov 5, 2026 |
About STLN
Starling Oncology, Inc., an oncology company, provides various oncology services in the United States. It operates through three segments: Specialty pharmacy, Patient Services, and Clinical Trials & Other. The company offers physician services, in-house infusion, in-house specialty pharmacy, clinical trials, radiation therapy, and outpatient blood product transfusion services, as well as educational seminars, support groups, counseling services, and 24/7 patient assistance and support services. It also manages clinical trials and palliative car... [Read more]
Financial Performance
In 2025, Starling Oncology's revenue was $502.73 million, an increase of 27.79% compared to the previous year's $393.41 million. Losses were -$50.31 million, -5.09% less than in 2024.
Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for STLN stock is "Strong Buy." The 12-month stock price target is $9.25, which is an increase of 164.29% from the latest price.
News
Starling Oncology management to meet virtually with BTIG
Virtual Meeting to be held on November 12 hosted by BTIG.
Starling Oncology price target lowered to $10 from $11 at B. Riley
B. Riley lowered the firm’s price target on Starling Oncology (STLN) to $10 from $11 and keeps a Buy rating on the shares following the Q3 report. The firm says…
Starling Oncology price target lowered to $8 from $10 at Lake Street
Lake Street lowered the firm’s price target on Starling Oncology (STLN) to $8 from $10 and keeps a Buy rating on the shares. Investors “disliked the company’s updated capitated revenue…
Starling Oncology reports Q3 EPS (13c) vs. (14c) last year
Reports Q3 revenue $169.77M, consensus $168.69M. Daniel Virnich, CEO of Starling, commented, “The third quarter of 2026 was another strong quarter for our company, with revenue up 24% year over…
Starling Oncology sees Q4 adjusted EBITDA $3M-$5M
The company said, “For the fourth quarter of 2026, we anticipate Adjusted EBITDA of $3 million to $5 million, as the Company onboards and ramps our Florida delegated lives.” Published…
Starling Oncology narrows FY26 revenue view to $650M-$660M from $650M-$670M
Consensus $665.01M. narrows FY26 adjusted EBITDA view to $4M-$6M from $2M-$7M.
Starling Oncology Earnings Call Transcript: Q3 2026
Q3 revenue grew 24.3% YoY to $169.8M, with positive Adjusted EBITDA of $3.4M and improved sequential MLR. 2026 guidance was updated, while 2027 capitation growth and high-teens normalized pharmacy margins remain key expectations.
Starling Oncology Earnings release: Q3 2026
Starling Oncology released its Q3 2026 earnings on November 5, 2026, summarizing the period's financial results.
Starling Oncology Quarterly report: Q3 2026
Starling Oncology has published its Q3 2026 quarterly earnings report on November 5, 2026.
Starling Oncology Reports Third Quarter 2026 Financial Results and Updates Full-Year 2026 Guidance
CERRITOS, Calif., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Starling Oncology, Inc. (NASDAQ: STLN) (“STLN” or the “Company”), one of the largest value-based community oncology groups in the United States, tod...
Starling Oncology Announces Third Quarter 2026 Earnings Release Date and Conference Call
CERRITOS, Calif., Oct. 26, 2026 (GLOBE NEWSWIRE) -- Starling Oncology, Inc. (“STLN”) (NASDAQ: STLN) a pioneer in value-based community oncology care, today announced that the company will release its ...
Starling Oncology price target raised to $9 from $7 at Needham
Needham raised the firm’s price target on Starling Oncology (STLN) to $9 from $7 and keeps a Buy rating on the shares after hosting a non-deal roadshow with its CEO…
Starling Oncology management to meet with B. Riley
Meeting to be held in South Florida on October 8-9 hosted by B. Riley.
Starling Oncology management to meet with Needham
Meeting to be held in New York on October 13 hosted by Needham.
Starling Oncology Leadership Highlights Recent and Upcoming Industry Conference Participation
Physician leaders share clinical insights on value-based therapy delivery, clinical trial access and integrated behavioral health in community oncology at major industry forums Physician leaders share...
Starling Oncology Transcript: Wells Fargo 21st Annual Healthcare Conference
Achieved first fully profitable year, doubled down on capital-light growth, and expanded delegated contracts across multiple states. Pharmacy now drives over 60% of revenue with rising margins, and robust pipeline supports a 2027 goal to double capitated revenue.
Starling Oncology Slides: Investor presentation
Starling Oncology has posted slides in relation to its latest quarterly earnings report, which was published on September 8, 2026.
Starling Oncology to Participate in Wells Fargo Healthcare Conference
CERRITOS, Calif., Aug. 24, 2026 (GLOBE NEWSWIRE) -- Starling Oncology™, Inc. (NASDAQ: STLN), (“STLN” or the “Company”), one of the largest value-based community oncology groups in the United States, t...
Starling Oncology Launches Starling Nexus™, a Technology Platform Built to Optimize Oncology Provider Engagement and Accelerate High-Quality Care at Scale
CERRITOS, Calif., Aug. 17, 2026 (GLOBE NEWSWIRE) -- Starling Oncology™ Inc. (NASDAQ: STLN), (“STLN” or the “Company”), one of the largest value-based community oncology groups in the United States, to...
Starling Oncology price target raised to $11 from $8 at B. Riley
B. Riley raised the firm’s price target on Starling Oncology (STLN) to $11 from $8 and keeps a Buy rating on the shares. The company guided capitated revenue to double…
Starling Oncology Earnings Call Transcript: Q2 2026
Q2 2026 saw record revenue, positive adjusted EBITDA, and a successful refinancing that improved liquidity. New capitation contracts in Nevada, Oregon, and California drove growth, while guidance for 2026 was raised on strong specialty pharmacy performance.
Starling Oncology Earnings release: Q2 2026
Starling Oncology released its Q2 2026 earnings on August 6, 2026, summarizing the period's financial results.
Starling Oncology Quarterly report: Q2 2026
Starling Oncology has published its Q2 2026 quarterly earnings report on August 6, 2026.
Starling Oncology Reports Second Quarter 2026 Financial Results and Updates Full-Year 2026 Guidance
CERRITOS, Calif., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Starling Oncology, Inc. (NASDAQ: STLN) (“STLN” or the “Company”), one of the largest value-based community oncology groups in the United States, tod...
The Oncology Institute Rebrands as Starling Oncology
CERRITOS, Calif., Aug. 03, 2026 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. ("TOI" or “the Company”), one of the largest value-based oncology groups in the United States, announced today that it ...